DKK1: A Promising Drug Target and Biomarker for Disease (G22943)

Target Name: DKK1

NCBI ID: G22943

DKK1

DKK1: A Promising Drug Target and Biomarker for Disease

DKK1 (Dickkopf-1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The protein encoded by DKK1 is a non-protein kinase that is expressed in various tissues and cell types, including neurons, endothelial cells, and immune cells. DKK1 has been shown to play a role in several cellular processes, including cell signaling, cell adhesion, and inflammation.

DKK1 as a Drug Target

DKK1 has emerged as a promising drug target due to its involvement in several cellular processes that are associated with the development and progression of various diseases. One of the key mechanisms by which DKK1 is thought to contribute to disease is its role in cell signaling. DKK1 has been shown to play a role in several signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival.

In addition to its role in cell signaling, DKK1 has also been shown to contribute to the development and progression of several diseases. For example, DKK1 has been shown to be involved in the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. In addition, DKK1 has also been shown to be involved in the development of cancer, including melanoma and colorectal cancer.

DKK1 as a Biomarker

In addition to its role as a drug target, DKK1 has also been shown to be a potential biomarker for several diseases. For example, DKK1 has been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. In addition, DKK1 has also been shown to be involved in the development of cancer, including melanoma and colorectal cancer.

One of the key advantages of using DKK1 as a biomarker is its potential ability to serve as a therapeutic target. By inhibiting the activity of DKK1, researchers may be able to reduce the development and progression of neurodegenerative disorders and cancer. In addition, DKK1 may also be a useful biomarker for tracking the effectiveness of treatments for these disorders.

Conclusion

DKK1 is a gene that has been shown to play a role in several cellular processes that are associated with the development and progression of various diseases. As a result, DKK1 has emerged as a promising drug target and biomarker for a variety of conditions. Further research is needed to fully understand the role of DKK1 in disease and to develop effective treatments.

Protein Name: Dickkopf WNT Signaling Pathway Inhibitor 1

Functions: Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6 (PubMed:22000856). DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease (PubMed:17143291). Inhibits the pro-apoptotic function of KREMEN1 in a Wnt-independent manner, and has anti-apoptotic activity (By similarity)

The "DKK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DKK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets